Karam Al-Doori

Biography:

Karam graduated from the University of Aberdeen in 2020 with an MSci degree in Pharmacology. As part of his honours project, he focused on delineating the pharmacology of the CB2 cannabinoid receptor as a potential therapeutic target for prostate cancer. More recently, he has worked as a research scientist for Cambridge Glycoscience, a Cambridge-based start-up; aimed at producing sustainable and prebiotic sugar obtained from agricultural waste. He aims to utilise his prior experiences in both academic and industrial environments during his PhD at the MRC Toxicology Unit.

Research interests:

Disruption of mitochondrial function is a common cause of adverse drug reactions and mitochondrial toxicity is thought to be responsible for up to 50% of post-market drug withdrawals. Mitochondrial toxins often have a differential effect on tissue function.

Karam’s research focuses on how mitochondrial translation is influenced by toxic injury, investigating how mitochondrial tRNAs are affected and changed as a result of exposure to therapeutic agents; with the hope of improving understanding of mitochondrial toxicity in various cell types.